Oxybutynin - Penwest Pharmaceuticals
Alternative Names: Cystrin; Cystrin CR; Oxybutynin ER - Penwest PharmaceuticalsLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Penwest Pharmaceuticals
- Developer Sanofi; Schering Oy
- Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Urinary incontinence
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 07 Aug 2003 Clinical trials in Urinary incontinence in USA (PO)
- 07 Mar 2003 Leiras Oy has merged with Schering Oy